271 related articles for article (PubMed ID: 21915801)
21. Increased interleukin-10 production by ASC-deficient CD4+ T cells impairs bystander T-cell proliferation.
Narayan S; Kolly L; So A; Busso N
Immunology; 2011 Sep; 134(1):33-40. PubMed ID: 21718313
[TBL] [Abstract][Full Text] [Related]
22. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
[TBL] [Abstract][Full Text] [Related]
23. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
[TBL] [Abstract][Full Text] [Related]
24. Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.
Cicchelero L; Denies S; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
Cancer Lett; 2017 Aug; 400():205-218. PubMed ID: 27693635
[TBL] [Abstract][Full Text] [Related]
25. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
Li J; Wang S; Wang N; Zheng Y; Yang B; Wang X; Zhang J; Pan B; Wang Z
Cell Commun Signal; 2021 Aug; 19(1):89. PubMed ID: 34461944
[TBL] [Abstract][Full Text] [Related]
26. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
Denies S; Cicchelero L; de Rooster H; Daminet S; Polis I; Van de Maele I; Sanders NN
Vet Comp Oncol; 2017 Jun; 15(2):594-605. PubMed ID: 26961119
[TBL] [Abstract][Full Text] [Related]
27. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.
Mkrtichyan M; Najjar YG; Raulfs EC; Abdalla MY; Samara R; Rotem-Yehudar R; Cook L; Khleif SN
Eur J Immunol; 2011 Oct; 41(10):2977-86. PubMed ID: 21710477
[TBL] [Abstract][Full Text] [Related]
28. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
[TBL] [Abstract][Full Text] [Related]
29. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
[TBL] [Abstract][Full Text] [Related]
30. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.
Pepe FF; Cazzaniga ME; Baroni S; Riva F; Cicchiello F; Capici S; Cogliati V; Maggioni C; Cordani N; Cerrito MG; Malandrin S
BMC Cancer; 2022 Sep; 22(1):956. PubMed ID: 36068484
[TBL] [Abstract][Full Text] [Related]
32. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer.
Solis-Castillo LA; Garcia-Romo GS; Diaz-Rodriguez A; Reyes-Hernandez D; Tellez-Rivera E; Rosales-Garcia VH; Mendez-Cruz AR; Jimenez-Flores JR; Villafana-Vazquez VH; Pedroza-Gonzalez A
Breast Cancer; 2020 Sep; 27(5):837-849. PubMed ID: 32180141
[TBL] [Abstract][Full Text] [Related]
33. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
[TBL] [Abstract][Full Text] [Related]
34. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
Perez SA; Karamouzis MV; Skarlos DV; Ardavanis A; Sotiriadou NN; Iliopoulou EG; Salagianni ML; Orphanos G; Baxevanis CN; Rigatos G; Papamichail M
Clin Cancer Res; 2007 May; 13(9):2714-21. PubMed ID: 17473204
[TBL] [Abstract][Full Text] [Related]
35. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
Zhu S; Lin J; Qiao G; Xu Y; Zou H
Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
[TBL] [Abstract][Full Text] [Related]
36. Chemoresistance in mesenchymal lung cancer cells is correlated to high regulatory T cell presence in the tumor microenvironment.
Zhang LN; Xin T; Chen M; Gao P
IUBMB Life; 2019 Jul; 71(7):986-991. PubMed ID: 31066485
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus.
Zhang L; Bertucci AM; Ramsey-Goldman R; Burt RK; Datta SK
J Immunol; 2009 Nov; 183(10):6346-58. PubMed ID: 19841178
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.
Finke JH; Rini B; Ireland J; Rayman P; Richmond A; Golshayan A; Wood L; Elson P; Garcia J; Dreicer R; Bukowski R
Clin Cancer Res; 2008 Oct; 14(20):6674-82. PubMed ID: 18927310
[TBL] [Abstract][Full Text] [Related]
39. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
40. In vivo depletion of CD4+CD25+ regulatory T cells in cats.
Smithberg SR; Fogle JE; Mexas AM; Reckling SK; Lankford SM; Tompkins MB; Dean GA
J Immunol Methods; 2008 Jan; 329(1-2):81-91. PubMed ID: 17980384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
